Mission: Strategically, Alexza is focused on finding new therapeutic solutions for conditions that would benefit from rapid, precise and non-invasive treatment. For certain conditions, patients and physicians are in need of products with rapid onset of effect, ease of use, non-invasive ...
I have been working at Alexza Pharmaceuticals full-time (Less than a year)
great culture, good financial position
none that I can think of
Advice to Management
President & COO Tatjana Naranda, good job, keep up the good work!
My total interview time last about 6-7 hours over one phone interview and two separate days. I talked to 8 different people total, almost half of them in senior management. That was probably the most intimidating part, interviewing with directors, VPs, and Sr. VPs, but surprisingly, it was pretty straightforward. Each of my interviewers asked me almost identical questions, all pertaining to my previous work experience. One of them actually went down my resume and had specific questions about each line item I had written down on my resume, which I thought was helpful since I am very familiar with I had put down. The interviewers were also honest with their own experience at the company and gave me realistic expectations, which I appreciated.
Engage Therapeutics Announces $23 Million Series A Financing to Advance Phase 2b Development of Novel Epileptic Seizure Rescue Therapy SUMMIT, N.J., Sep. 27, 2017 – Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced today the closing of its $23 million Series A financing round. Engage will use the proceeds from the financing to fund a Phase 2b clinical trial of its lead candidate Staccato® alprazolam, an acute epileptic treatment designed to stop seizure activity.
See the whole story at http://glassdoor.com/slink.htm?key=vQRyz
Galen US Inc. Acquires First Inhaled Therapy Approved to Treat Agitation Associated with Schizophrenia and Bipolar I Disorder, Announces Revised Labeling
ADASUVE® (loxapine) inhalation powder is the first and only orally inhaled medicine approved for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
SOUDERTON PA, September 26, 2017 – Galen US Inc. today announced its acquisition of the US commercial rights to ADASUVE® , an orally inhaled form of the typical antipsychotic loxapine, from Alexza Pharmaceuticals, Inc. ADASUVE is the first and only FDA-approved inhaled therapy for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. 1 ADASUVE offers a novel solution which allows for rapid systemic delivery by inhalation of a thermally-generated aerosol of loxapine to the lung.
See the whole story at http://glassdoor.com/slink.htm?key=vQRyV
Let us know if we're missing any workplace or industry recognition –